These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34539759)

  • 1. GM1 Gangliosidosis-A Mini-Review.
    Nicoli ER; Annunziata I; d'Azzo A; Platt FM; Tifft CJ; Stepien KM
    Front Genet; 2021; 12():734878. PubMed ID: 34539759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein modeling and clinical description of a novel in-frame GLB1 deletion causing GM1 gangliosidosis type II.
    Richter JE; Zimmermann MT; Blackburn PR; Mohammad AN; Klee EW; Pollard LM; Macmurdo CF; Atwal PS; Caulfield TR
    Mol Genet Genomic Med; 2018 Nov; 6(6):1229-1235. PubMed ID: 30187681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of glycan substrates accumulating in GM1 Gangliosidosis.
    Lawrence R; Van Vleet JL; Mangini L; Harris A; Martin N; Clark W; Chandriani S; LeBowitz JH; Giugliani R; d'Azzo A; Yogalingam G; Crawford BE
    Mol Genet Metab Rep; 2019 Dec; 21():100524. PubMed ID: 31720227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case reports of juvenile GM1 gangliosidosisis type II caused by mutation in GLB1 gene.
    Karimzadeh P; Naderi S; Modarresi F; Dastsooz H; Nemati H; Farokhashtiani T; Shamsian BS; Inaloo S; Faghihi MA
    BMC Med Genet; 2017 Jul; 18(1):73. PubMed ID: 28716012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human
    Latour YL; Yoon R; Thomas SE; Grant C; Li C; Sena-Esteves M; Allende ML; Proia RL; Tifft CJ
    Mol Genet Metab Rep; 2019 Dec; 21():100513. PubMed ID: 31534909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sialidase NEU3 action on GM1 ganglioside is neuroprotective in GM1 gangliosidosis.
    Allende ML; Lee YT; Byrnes C; Li C; Tuymetova G; Bakir JY; Nicoli ER; James VK; Brodbelt JS; Tifft CJ; Proia RL
    J Lipid Res; 2023 Dec; 64(12):100463. PubMed ID: 37871851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glb1 knockout mouse model shares natural history with type II GM1 gangliosidosis patients.
    Nicoli ER; Huebecker M; Han ST; Garcia K; Munasinghe J; Lizak M; Latour Y; Yoon R; Glase B; Tyrlik M; Peiravi M; Springer D; Baker EH; Priestman D; Sidhu R; Kell P; Jiang X; Kolstad J; Kuhn AL; Shazeeb MS; Acosta MT; Proia RL; Platt FM; Tifft CJ
    Mol Genet Metab; 2023 Feb; 138(2):107508. PubMed ID: 36709532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy approaches for GM1 gangliosidosis: Focus on animal and cellular studies.
    Hosseini K; Fallahi J; Tabei SMB; Razban V
    Cell Biochem Funct; 2023 Dec; 41(8):1093-1105. PubMed ID: 38018878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis.
    Regier DS; Kwon HJ; Johnston J; Golas G; Yang S; Wiggs E; Latour Y; Thomas S; Portner C; Adams D; Vezina G; Baker EH; Tifft CJ
    Am J Med Genet A; 2016 Mar; 170(3):634-44. PubMed ID: 26646981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-one novel mutations in the GLB1 gene identified in a large group of GM1-gangliosidosis and Morquio B patients: possible common origin for the prevalent p.R59H mutation among gypsies.
    Santamaria R; Chabás A; Coll MJ; Miranda CS; Vilageliu L; Grinberg D
    Hum Mutat; 2006 Oct; 27(10):1060. PubMed ID: 16941474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GM1 Gangliosidosis Type II: Results of a 10-Year Prospective Study.
    D'Souza P; Farmer C; Johnston J; Han ST; Adams D; Hartman AL; Zein W; Huryn LA; Solomon B; King K; Jordan C; Myles J; Nicoli ER; Rothermel CE; Algarin YM; Huang R; Quimby R; Zainab M; Bowden S; Crowell A; Buckley A; Brewer C; Regier D; Brooks B; Baker E; Vézina G; Thurm A; Tifft CJ
    medRxiv; 2024 Jan; ():. PubMed ID: 38313286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The skeletal phenotype of intermediate GM1 gangliosidosis: Clinical, radiographic and densitometric features, and implications for clinical monitoring and intervention.
    Ferreira CR; Regier DS; Yoon R; Pan KS; Johnston JM; Yang S; Spranger JW; Tifft CJ
    Bone; 2020 Feb; 131():115142. PubMed ID: 31704340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings.
    Caciotti A; Garman SC; Rivera-Colón Y; Procopio E; Catarzi S; Ferri L; Guido C; Martelli P; Parini R; Antuzzi D; Battini R; Sibilio M; Simonati A; Fontana E; Salviati A; Akinci G; Cereda C; Dionisi-Vici C; Deodato F; d'Amico A; d'Azzo A; Bertini E; Filocamo M; Scarpa M; di Rocco M; Tifft CJ; Ciani F; Gasperini S; Pasquini E; Guerrini R; Donati MA; Morrone A
    Biochim Biophys Acta; 2011 Jul; 1812(7):782-90. PubMed ID: 21497194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice.
    Chen JC; Luu AR; Wise N; Angelis R; Agrawal V; Mangini L; Vincelette J; Handyside B; Sterling H; Lo MJ; Wong H; Galicia N; Pacheco G; Van Vleet J; Giaramita A; Fong S; Roy SM; Hague C; Lawrence R; Bullens S; Christianson TM; d'Azzo A; Crawford BE; Bunting S; LeBowitz JH; Yogalingam G
    J Biol Chem; 2020 Sep; 295(39):13532-13555. PubMed ID: 31481471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis.
    Tsunogai T; Ohashi T; Shimada Y; Higuchi T; Kimura A; Watabe AM; Kato F; Ida H; Kobayashi H
    Mol Ther Methods Clin Dev; 2022 Jun; 25():448-460. PubMed ID: 35615711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive behavioral and biochemical outcomes of novel murine models of GM1-gangliosidosis and Morquio syndrome type B.
    Przybilla MJ; Ou L; Tăbăran AF; Jiang X; Sidhu R; Kell PJ; Ory DS; O'Sullivan MG; Whitley CB
    Mol Genet Metab; 2019 Feb; 126(2):139-150. PubMed ID: 30528226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic challenge for the rare lysosomal storage disease: Late infantile GM1 gangliosidosis.
    Lee JS; Choi JM; Lee M; Kim SY; Lee S; Lim BC; Cheon JE; Kim IO; Kim KJ; Choi M; Seong MW; Chae JH
    Brain Dev; 2018 May; 40(5):383-390. PubMed ID: 29439846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
    Condori J; Acosta W; Ayala J; Katta V; Flory A; Martin R; Radin J; Cramer CL; Radin DN
    Mol Genet Metab; 2016 Feb; 117(2):199-209. PubMed ID: 26766614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GM1 gangliosidosis: patients with different phenotypic features and novel mutations.
    Emecen Sanli M; Dogan M
    J Pediatr Endocrinol Metab; 2023 Jun; 36(6):602-607. PubMed ID: 37042746
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.